LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. (LRMR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C (2.2) | C- (2.1) | D (1.3) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | C (2.2) | C (2.2) | D (1.5) | C+ (2.7) | C (2.2) |
| 2026-10-30 | C+ (2.5) | C (2.2) | C (2.2) | D+ (1.8) | C+ (2.7) | C (2.3) |
| 2026-10-23 | C+ (2.5) | C- (2.1) | C (2.2) | D+ (1.8) | C+ (2.6) | C (2.2) |
| 2026-10-16 | C+ (2.5) | C- (2.1) | C (2.2) | D+ (1.8) | C+ (2.6) | C (2.2) |